%0 Journal Article
%B Cardiovasc Diabetol
%D 2018
%G eng
%N 1
%P 39
%R 10.1186/s12933-018-0682-3
%T Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio
%V 17
%1 https://www.ncbi.nlm.nih.gov/pubmed/29540217?dopt=Abstract